The American College of Physicians (ACP) has issued a new guideline regarding treatment of osteoporosis to prevent fracture. 

Among other things, the guideline offers a strong recommendation that clinicians offer pharmacologic treatment with alendronate, risedronate, zoledronic acid, or denosumab to reduce the risk for hip and vertebral fractures in women who have known osteoporosis, and a strong recommendation against the use of menopausal estrogen therapy or menopausal estrogen plus progestogen therapy or raloxifene for treatment of osteoporosis in women. Learn more...

Please login to comment
  • No comments found

Submit Community Content

If you have orthopedic information that you would like to share with the Orthogate Community, please register/login and submit your news, event, job, article, case or workshop from the Submit Content menu under the My Account area. Learn more!